As per MRFR analysis, the UK Sacroiliitis Market Size was estimated at 9.17 (USD Million) in 2023. The UK Sacroiliitis Market Industry is expected to grow from 10.92(USD Million) in 2024 to 54.68 (USD Million) by 2035. The UK Sacroiliitis Market CAGR (growth rate) is expected to be around 15.768% during the forecast period (2025 - 2035).
Key UK Sacroiliitis Market Trends Highlighted
The UK Sacroiliitis Market is experiencing notable trends driven by increasing awareness of inflammatory arthritis conditions. Healthcare professionals are emphasizing early diagnosis and treatment of sacroiliitis, which is leading to the growth of specialized clinics and diagnostic centers across the UK. Rising incidences of back pain, coupled with a growing aging population, are also influencing the demand for effective treatments and management options. Notably, the use of biological drugs and physical therapy modalities has been on the rise, shaping the treatment landscape significantly.
Opportunities within the UK market are expanding, particularly due to advancements in telemedicine and digital health platforms.These technologies facilitate better patient access to care, especially in rural areas where healthcare resources may be limited. The higher adoption of personalized medicine and tailored treatment plans could further enhance patient outcomes, presenting a strong opportunity for healthcare innovators to capture this evolving demand. The UK government’s initiatives to support healthcare and research advancements offer a conducive environment for introducing new therapeutic options.
In recent times, there has been a shift toward holistic approaches in managing sacroiliitis as healthcare providers recognize the importance of overall well-being.Integrative treatments, including lifestyle changes, physiotherapy, and nutrition, are gaining attention alongside traditional medical therapies. Additionally, patient education is becoming a high priority, with growing resources available to help individuals understand their conditions better. Collectively, these trends indicate a proactive approach to managing sacroiliitis in the UK, leading to a more comprehensive and patient-centered healthcare landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
UK Sacroiliitis Market Drivers
Increase in Prevalence of Autoimmune Diseases
The UK Sacroiliitis Market Industry is heavily influenced by the increased prevalence of autoimmune illnesses, which has been continuously increasing over the last decade. According to the National Health Service (NHS), illnesses such as ankylosing spondylitis, which is frequently associated with sacroiliitis, had a 30% increase in hospital admissions between 2015 and 2020.
Growing awareness of these disorders, as well as advances in diagnosis, are focusing more attention on treatment alternatives. This rise, combined with organizations such as Arthritis Research UK, which campaigns for research and assistance, demonstrates a need for new medicines and adds to market growth prospects in the UK Sacroiliitis Market Industry. Furthermore, as healthcare systems adjust to these growing cases, the need for focused treatments is projected to increase, driving the market upward as new medicines are offered.
Advancements in Medical Technology
The continuous advancements in medical technology are playing a crucial role in the growth of the UK Sacroiliitis Market Industry. Innovations such as minimally invasive surgical techniques and advanced imaging technologies, including MRI, allow for better diagnosis and management of sacroiliitis.
The UK government's investment in health technology, as seen through initiatives like the Accelerated Access Collaborative, is intended to fast-track new innovations into the healthcare system, thereby increasing patient access to cutting-edge treatment options.These advancements are projected to improve patient outcomes and reduce the long-term healthcare burden, showcasing the potential for robust growth in the market.
Growing Awareness and Education about Sacroiliitis
Increasing awareness and educational initiatives surrounding sacroiliitis are major drivers for the UK Sacroiliitis Market Industry. Patient advocacy groups, such as the UK Spondyloarthritis Society, have actively worked to enhance public understanding of sacroiliitis and its symptoms.
A recent campaign launched in 2022, focused on reducing the diagnostic delay for spondyloarthritis, has been endorsed by over 50 healthcare professionals, promoting better early intervention.Public health messages that emphasize recognizing signs and symptoms of sacroiliitis are projected to improve diagnosis rates, consequently leading to increased treatment options and driving market growth.
UK Sacroiliitis Market Segment Insights
Sacroiliitis Market Diagnosis Insights
The UK Sacroiliitis Market, specifically within the Diagnosis segment, is experiencing notable advancements due to the increasing prevalence of sacroiliitis and related inflammatory conditions. Imaging Tests play a pivotal role in diagnostics, as they enable healthcare professionals to effectively assess sacroiliac joint inflammation and rule out other potential causes of pain. Techniques such as magnetic resonance imaging and computed tomography are employed frequently to visualize joint abnormalities and guide treatment decisions.
The growing awareness around the importance of accurate diagnosis is driving the demand for sophisticated imaging technologies.Moreover, Anesthetic Injections are also becoming an integral part of the diagnostic process, often used both as a therapeutic measure and as a method to confirm diagnosis through pain relief. Such injections help healthcare providers determine whether the sacroiliac joint is the source of pain, significantly aiding in crafting a more personalized treatment plan.
With these diagnostic tools becoming widely adopted, the UK healthcare landscape reflects a trend where early and accurate diagnosis leads to better treatment outcomes, accordingly influencing the overall healthcare system and underlining the need for continual investment in medical technology and training.As the push for advanced diagnostics rises, the integration of these methodologies is expected to enhance the capabilities of clinicians, further shaping the future of the Diagnosis segment within the UK Sacroiliitis Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Sacroiliitis Market Treatment Insights
The Treatment segment of the UK Sacroiliitis Market is drawing attention due to the rising prevalence of sacroiliitis and expanding awareness regarding effective treatment methods. The segment is diverse, encompassing various approaches such as Medications, Joint Injections, Joint Fusion, and Radiofrequency Denervation. Medications, particularly non-steroidal anti-inflammatory drugs, are widely utilized for initial pain management. Joint Injections, including corticosteroids, are preferred for localized pain relief, offering significant benefits to patients when utilized effectively.Joint Fusion has gained traction as a long-term solution for structurally unstable joints, particularly among patients suffering from chronic sacroiliitis.
Radiofrequency Denervation is emerging as a minimally invasive procedure, providing substantial pain relief while reducing the need for surgical intervention. The growth in this market segment is driven by factors including an increasing aging population, higher incidences of inflammatory conditions, and advancements in surgical techniques and pain management therapies. With an expanding pipeline of innovative products and treatment options, the Treatment segment represents a critical component of the broader UK Sacroiliitis Market revenue landscape, contributing to overall improved patient outcomes and quality of life.Furthermore, ongoing research and clinical trials may pave the way for more effective treatment modalities, addressing patient needs in a more comprehensive manner.
Sacroiliitis Market End User Insights
The UK Sacroiliitis Market, particularly within the End User segment, demonstrates a growing demand driven by the increasing prevalence of sacroiliitis and related discomfort among the population. Hospitals play a pivotal role as they serve as primary care centers for diagnosis and treatment, equipped with advanced technologies and skilled healthcare professionals. The rising trend of outpatient procedures also positions hospitals as significant contributors to the market, as more patients seek effective pain management solutions in these facilities.Diagnostic centers hold substantial importance as well, offering specialized testing and imaging services crucial for accurate diagnosis and patient-specific treatment plans.
As healthcare policies evolve in the UK, the focus on early diagnosis and personalized medicine creates opportunities for both hospitals and diagnostic centers to enhance their service offerings, leading to improved patient outcomes. With robust government initiatives supporting healthcare infrastructure, the End User segment is poised for significant growth, driven by increasing awareness of sacroiliitis and its management options among clinicians and patients alike.Enhanced focus on research and development in these facilities highlights the potential for innovation in treatment methodologies within the UK Sacroiliitis Market, catering to the burgeoning need for effective clinical solutions.
UK Sacroiliitis Market Key Players and Competitive Insights
The UK Sacroiliitis Market is characterized by a diverse range of participants, including pharmaceutical companies, biotech firms, and healthcare providers. The increasing prevalence of sacroiliitis among the population poses significant challenges for patients and presents opportunities for companies specializing in pain management and inflammatory disorders. Competitive dynamics in this market are influenced by various factors, including innovation in drug development, regulatory approvals, and the ongoing emphasis on personalized medicine. Companies are focusing on enhancing their research and development capabilities to introduce novel treatments that target the underlying causes of sacroiliitis while addressing the symptoms associated with the condition. As the competition intensifies, firms strive to establish robust distribution networks and strategic partnerships to extend their market reach in the UK.
GlaxoSmithKline has a notable presence in the UK Sacroiliitis Market, supported by its extensive portfolio of anti-inflammatory medications and biologics targeting autoimmune conditions. The company's commitment to research and development allows for the continuous improvement of its therapeutic offerings, particularly for patients suffering from sacroiliitis. With a strong emphasis on clinical trials and collaborations with healthcare professionals, GlaxoSmithKline aims to enhance patient outcomes and ensure timely access to effective treatments. The company's established reputation within the pharmaceutical industry, combined with its investment in innovative therapies, positions it favorably in the competitive landscape. Additionally, GlaxoSmithKline benefits from its extensive distribution network and robust market presence, which enable it to cater to the growing demand for effective treatments in the UK.
Amgen is also a key player in the UK Sacroiliitis Market, recognized for its commitment to providing cutting-edge biological therapies. This company offers several important products aimed at inflammatory conditions, which are critical for the management of sacroiliitis. Amgen's strengths lie in its strong research and development capabilities, with a focus on developing novel therapeutic agents that address the unmet needs of patients. In recent years, Amgen has strategically engaged in partnerships and alliances to enhance its market position and accelerate its product pipeline. The company's efforts in mergers and acquisitions have allowed it to expand its therapeutic offerings and strengthen its foothold in the UK market, making it a formidable competitor. Through a combination of innovative therapies and strategic initiatives, Amgen continues to play a significant role in shaping treatment protocols for sacroiliitis, ultimately contributing to improved patient care and outcomes within the UK healthcare landscape.
Key Companies in the UK Sacroiliitis Market Include:
UK Sacroiliitis Market Industry Developments
In recent months, the UK Sacroiliitis Market has been witnessing significant developments, particularly among key players such as GlaxoSmithKline, Amgen, and Bristol-Myers Squibb. A notable growth trajectory has been reported, attributed largely to advancements in treatment options and a surge in market valuation driven by innovations in biopharmaceuticals and targeted therapies.
For instance, in September 2023, AbbVie announced the successful outcome of clinical trials for a new drug aimed at treating Sacroiliitis, which is anticipated to enhance its market share. Additionally, Merck and Co are reportedly exploring strategic partnerships to develop next-generation therapies, demonstrating the competitive nature of the market. In terms of mergers and acquisitions, a notable movement occurred in June 2023 when UCB acquired a smaller biotechnology firm focused on Sacroiliitis treatment, strengthening its pipeline.
Market growth has been further influenced by increased investment in Research and Development initiatives across major companies, including Roche and Gilead Sciences, which are keen to capture a larger footprint in the UK healthcare landscape. Furthermore, the overall increase in patients seeking specialized treatment for inflammatory diseases underlines the rising importance of this specific market segment.
UK Sacroiliitis Market Segmentation Insights
Sacroiliitis Market Diagnosis Outlook
Sacroiliitis Market Treatment Outlook
Sacroiliitis Market End User Outlook
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 9.17(USD Million) |
| MARKET SIZE 2024 | 10.92(USD Million) |
| MARKET SIZE 2035 | 54.68(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.768% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | GlaxoSmithKline, Amgen, BristolMyers Squibb, Merck & Co, AbbVie, UCB, Celgene, Roche, Gilead Sciences, Sanofi, Biogen, Novartis, Johnson & Johnson, Pfizer |
| SEGMENTS COVERED | Diagnosis, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Increased prevalence awareness campaigns, Advanced diagnostic technologies adoption, Rising demand for personalized treatments, Expansion of telehealth services, Development of combination therapies |
| KEY MARKET DYNAMICS | increasing prevalence of autoimmune diseases, growing demand for effective treatments, advancements in diagnostic techniques, rising awareness of sacroiliitis, increasing healthcare expenditure in UK |
| COUNTRIES COVERED | UK |
Frequently Asked Questions (FAQ) :
The UK Sacroiliitis Market is expected to be valued at 10.92 million USD in 2024.
By 2035, the UK Sacroiliitis Market is projected to reach a value of 54.68 million USD.
The UK Sacroiliitis Market is anticipated to grow at a CAGR of 15.768% between 2025 and 2035.
Key players in the UK Sacroiliitis Market include GlaxoSmithKline, Amgen, Bristol Myers Squibb, and Merck & Co.
The market is divided into Imaging Tests and Anesthetic Injections for diagnosis.
In 2024, the market value for Imaging Tests is expected to be 5.5 million USD.
The market value for Anesthetic Injections is projected to be 27.18 million USD by 2035.
By 2035, the market size for Imaging Tests is expected to reach 27.5 million USD.
The growth drivers for the market include increased healthcare awareness and advancements in diagnostic technologies.
The market faces challenges such as high treatment costs and limited awareness among patients.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
